Abstract-Leptin, the product of the ob gene, has been shown to increase heart rate and blood pressure through a stimulation of cardiac sympathetic nervous system activity, a phenomenon also involved in the pathogenesis of left ventricular hypertrophy in hypertensives. Thus, we hypothesize that plasma leptin concentration is associated with left ventricular hypertrophy. Forty hypertensive males and 15 healthy male subjects underwent anthropometric and echocardiographic evaluations, assessment of insulin sensitivity through euglycemic glucose clamp combined with indirect calorimetry, and determination of fasting plasma leptin concentration. Fasting plasma leptin levels were higher in hypertensives than in controls (6.48Ϯ2.9 versus 4.62Ϯ1.5 ng/mL, PϽ0.05); these results were unchanged after adjustment for body mass index (PϽ0.05). In the whole group of patients (nϭ55), fasting plasma leptin concentration was correlated with body mass index (rϭ0.46, PϽ0.001) and waist/hip ratio (rϭ0.50, PϽ0.001); independent of body mass index and waist/hip ratio, fasting plasma leptin concentration was correlated (nϭ55) with whole-body glucose disposal (rϭϪ0.27, PϽ0.04), interventricular septum thickness (rϭ0.34, PϽ0.001), posterior wall thickness (rϭ0.38, PϽ0.003), and the sum of wall thicknesses (rϭ0.68, PϽ0.001). In a multivariate analysis (nϭ55), age, body mass index, fasting plasma leptin concentration, plasma Na ϩ concentration, whole-body glucose disposal, and diastolic blood pressure explained 68% of the variability of the sum of wall thicknesses with fasting plasma leptin concentration (PϽ0.03), whole body glucose disposal (PϽ0.002), and diastolic blood pressure (PϽ0.001), which were significantly and independently associated with the sum of wall thicknesses. In conclusion, our study demonstrates that fasting plasma leptin levels are associated with increased myocardial wall thickness independent of body composition and blood pressure levels in hypertensives. (Hypertension. 1999;34:1047-1052.) Key Words: leptin Ⅲ hypertension, essential Ⅲ hypertension, arterial Ⅲ insulin L eptin, the product of the ob gene, 1 is a peptide hormone produced by adipose tissue involved in body weight control through a decrease in food intake and an increase in energy expenditure. 2 Several studies have shown leptin to increase in insulin-resistant states such as obesity 3 and hypertension. 4 Nevertheless, a direct relation between plasma leptin concentration and the cardiovascular system needs to be investigated. The possibility that leptin plays a role in the cardiovascular system is strengthened by the evidence that chronic leptin infusion has been shown to increase heart rate and blood pressure through stimulation of sympathetic nervous system activity. 5, 6 Interestingly, this latter phenomenon is also involved in the pathogenesis of left ventricular (LV) hypertrophy. 7,8 Thus, we hypothesize that plasma leptin concentration is associated with the presence of LV hypertrophy. To determine the accuracy of this hypothesis, we evaluated the possible association between plasma leptin levels and echocardiographic parameters of LV measurements in hypertensive patients.
L eptin, the product of the ob gene, 1 is a peptide hormone produced by adipose tissue involved in body weight control through a decrease in food intake and an increase in energy expenditure. 2 Several studies have shown leptin to increase in insulin-resistant states such as obesity 3 and hypertension. 4 Nevertheless, a direct relation between plasma leptin concentration and the cardiovascular system needs to be investigated. The possibility that leptin plays a role in the cardiovascular system is strengthened by the evidence that chronic leptin infusion has been shown to increase heart rate and blood pressure through stimulation of sympathetic nervous system activity. 5, 6 Interestingly, this latter phenomenon is also involved in the pathogenesis of left ventricular (LV) hypertrophy. 7, 8 Thus, we hypothesize that plasma leptin concentration is associated with the presence of LV hypertrophy. To determine the accuracy of this hypothesis, we evaluated the possible association between plasma leptin levels and echocardiographic parameters of LV measurements in hypertensive patients.
Methods Patients
Forty consecutive male patients with newly diagnosed slightly to moderate essential arterial hypertension and 15 adult male healthy subjects were enrolled after their informed consent was obtained. Patients were considered to be hypertensive according to their clinic blood pressure levels (diastolic blood pressure [DBP] Ͼ90 mm Hg, calculated as the mean of 3 different measurements in at least 3 different visits at 1-week intervals). Exclusion criteria from the study were a family history of diabetes and obesity, coronary artery disease, impaired glucose tolerance, and diabetes mellitus. All patients were free from cardiac medication and drugs known to interfere with glucose metabolism, and all had a similar sedentary lifestyle. More detailed information concerning the population studied is given in Table 1 . The study was approved by the ethical committees of our institutions.
Anthropometric Determinations
Weight and height were measured by standard techniques. Body fat and fatty free mass were measured using a 4-terminal bioimpedance analyzer (RJL Spectrum Bioelectrical Impedance, BIA 101/SC Akern, RJL-System). 9 Body mass index (BMI) was calculated as body weight divided by height squared. Waist circumference was measured at the midpoint between the lower rib margin and the iliac crest (normally the umbilical level), and hip circumference was measured at the trochanter level. Both circumferences were measured to the nearest 0.5 cm with plastic tape, and the ratio between them provided the waist/hip ratio (WHR).
Echocardiographic Determinations
Doppler echocardiographic examinations using a 2.5-MHz transducer connected to a Sector Imager 5000 (Ote-Biomedica) were performed with patients in a partial left decubitus position and recorded on strip-chart paper. At the end of the study, heart rate and cuff blood pressure (as the mean of 3 determinations) were estimated by a physician using a sphygmomanometer who was blinded to the results of the echocardiographic examination. Consecutive coded Doppler echocardiographic tracings were examined for Ն3 cardiac cycles by 2 experienced observers who were unaware of blood pressure and metabolic data of the subjects. M-mode measurements of the LV were performed at end diastole according to the recommendations of the American Society of Echocardiography. 10 The sum of wall thicknesses (SWT) was calculated as the sum of interventricular septum thickness (IVST) and posterior wall thickness (PWT). Relative diastolic wall thickness (RDWT) was determined as the ratio between SWT and LV end-diastolic diameter (LVEDD). Fractional shortening was calculated as the percentage of change in the internal LV dimension between systole and diastole. LV mass (LVM) was estimated by the Penn convention 11 and corrected for height in meters (LVM/height). 12 According to the values of LVM index, the study population was divided into 2 groups: one with LV hypertrophy (LVM index Ͼ141 g/m according to the Framingham criteria for men) 13 and one without LV hypertrophy. Echocardiographic cardiovascular determinations were carried out by investigators unaware of the metabolic data. Finally, cardiovascular and metabolic investigations were performed on different days.
Metabolic Determinations
All subjects had a normal glucose tolerance, which was assessed by oral glucose tolerance test (75 g glucose). 14 On a different day, a test involving a euglycemic hyperinsulinemic glucose clamp 15 was carried out. In this latter test, a fixed insulin infusion rate (7.1 pmol/kg per minute for 120 minutes) was set, and a variable amount of glucose (as 20% solution) was delivered. Whole-body glucose disposal (WBGD) was calculated during the final 60 minutes of the clamp procedure according to the following formula: WBGDϭglucose infusion rateϩpool correction (as described elsewhere 16 ). This calculation is valid when no entry of glucose in plasma from the liver occurs. In nondiabetic subjects 17 and hypertensive patients, 18 hepatic glucose output has been found to be fully suppressed during a glucose clamp, test at this insulin infusion rate. Furthermore, in preliminary clamps, an insulin infusion rate of 7.1 pmol/kg per minute fully suppressed (but without negative numbers) hepatic glucose output.
In the basal state (from Ϫ60 to 0 minutes) and during the last 60 minutes of the clamp procedure, indirect calorimetry estimated substrate oxidation. 19 A computerized open-circuit system to measure gas exchange through a 25-L PVC plastic canopy (Deltatrac, Datex) was used. The monitor has a precision of 2.6% for oxygen and 2.1% for carbon dioxide production. Protein oxidation was calculated from urea nitrogen excretion before and at the end of the glucose clamp procedure and corrected for the changes in urea pool. 19 Substrate oxidation rate was calculated from the oxygen consumption, the carbon oxide production, and the nitrogen urinary excretion rate according to Ferrannini. 19 Nonoxidative glucose metabolism (NOGM) was calculated as the difference between WBGD and oxidative glucose metabolism calculated by indirect calorimetry. 19 Metabolic tests were carried out by investigators unaware of the cardiovascular data.
Analytical Methods
Plasma glucose was immediately determined by the plasma glucose method (Autoanalyzer, Beckman). Blood samples for insulin measurements were collected in heparinized tubes. After centrifugation, serum insulin was determined by a commercially available radioimmunoassay kit (coefficient of variation 3.2Ϯ0.3%, Sorin, Biomedical). At baseline and at the end of the glucose clamp procedure, blood samples for plasma leptin concentration were drawn, and leptin concentrations were determined by radioimmunoassay (coefficient of variation 4.3Ϯ0.5%, Linco Research).
Calculation and Statistical Analysis
Mean blood pressure was calculated as DBP plus one-third pulse pressure. To approximate normal distribution, plasma leptin and Values are meanϮSD. FFM indicates free fatty mass; SBP, systolic blood pressure; and HR, heart rate.
plasma insulin were log-transformed (used in all calculations) and then back-transformed (used in the presentation of the results). All results are meanϮSD. ANOVA with the Scheffé test were used to compare the results between the groups. Simple correlations by the Pearson method allowed us to assess the univariate relations. ANCOVA was used for investigating the impact of BMI on differences in plasma leptin concentration. Multiple regression analysis allowed us to investigate the different contribution of each covariate to the variability in myocardial wall thickness. A value of PϽ0.05 was considered statistically significant. All statistical analyses were made on IBM PC computers by the SOLO software package (BMDP).
Results
Clinical characteristics of the study groups are reported in Table 1 . Patients and controls were adults and had a prevalent central body fat distribution without significant differences between the 2 groups. In contrast, hypertensive patients had worse insulin action (lower level of WBGD) than did control subjects. Fasting plasma (FP) leptin levels were higher in hypertensives than in control subjects, and such results were unchanged after adjustment for BMI (PϽ0.05). Insulin infusion did not affect baseline plasma leptin levels for either group (Figure 1) .
According to the presence of LV hypertrophy, hypertensives were categorized into 2 groups. Despite slight differences in BMI, plasma Na ϩ concentrations, and insulin action, plasma leptin levels did not differ in patients with and without LV hypertrophy (data not shown).
Because FP leptin levels were different in controls and hypertensives, the correlation analysis was made in the whole population (nϭ55) as well as in the control (nϭ15) and hypertensive (nϭ40) groups separately ( Table 2 ). In the whole population, FP leptin concentration was correlated positively with BMI, WHR, FP insulin, and basal lipid oxidation and negatively with WBGD and NOGM ( Table 2) . By group, all these correlations, except basal lipid oxidation, remained significant ( (Figure 2) , hypertensive patients had greater LVM/height, IVST, PWT, RDWT, and SWT than did controls. As far as the relation between FP leptin concentrations and cardiovascular variables is concerned (Table 3) , FP leptin concentration correlated positively with DBP, IVTS, PWT, SWT, RDWT, and plasma Na ϩ concentration in the whole population. In the hypertensive group, all these correlations, except DBP, remained significant, whereas in the control group no correlation reached statistical significance (Table 3 (Figure 3 ) remained significant. Such correlations did not remain significant in controls.
Among the different echocardiographic indexes, SWT is the most expressive index of the increase in myocardial wall thickness. For this reason, SWT was chosen as a dependent variable in the multiple linear stepwise regression analysis. Such analysis allowed us to investigate the independent role of main anthropometric and cardiovascular covariates on SWT variability (Table 4 ). In the whole population, a model that incorporated age, BMI, FP leptin concentration, plasma Na ϩ concentration, WBGD, and DBP explained 68% of SWT variability. In such a model, plasma leptin concentration (PϽ0.03), WBGD (PϽ0.002), and DBP (PϽ0.001) were significantly and independently associated with SWT. The same model was used for the hypertensive group, and it 
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explains 53% of SWT variability. In this model, only plasma leptin (PϽ0.01) and WBGD (PϽ0.04) were significantly and independently associated with SWT.
Discussion
The present study demonstrates that plasma leptin concentration (1) was higher in hypertensives patients than in control subjects, (2) did not correlate with LVM but was associated with echocardiographic indexes of increased wall thickness, (3) had the strongest association with SWT, and (4) was not affected by acute hyperinsulinemia. The higher FP leptin concentration found in hypertensive patients could be due to the occurrence of insulin resistance in this group. In fact, in the whole population compared with the hypertensive group, FP leptin concentration had a negative correlation with WBGD.
To the best of our knowledge, this is the first evidence showing a relation between plasma leptin levels and LV wall thickness (SWT). The evidence that leptin concentration did not correlate with LVM but with SWT was not unexpected. In fact, LV hypertrophy can be attributable to the increase of either wall thickness (concentric hypertrophy) or LVEDD (eccentric hypertrophy) or both, and no relation between plasma leptin levels and LVEDD was found. Because plasma leptin correlated with BMI and some of our patients were overweight, one could argue that the impact of plasma leptin on myocardial wall thickness was mainly driven by body weight. This was not the case. In fact, the relation between FP leptin levels and SWT was independent of anthropometric characteristics as well as of blood pressure levels; thus, FP leptin levels are independently associated with SWT variability.
Recently, SWT has been found to be associated to insulin resistance in arterial hypertension. 20 Because insulin resistance and leptin were also found to be associated in the present study, one could hypothesize that the link between plasma leptin levels and myocardial wall growth might be driven by insulin resistance. However, although much of the variability in SWT found in the present study was explained by insulin resistance, leptin remained independently associated with SWT in the multivariate model, even after adjusting for insulin action. This finding suggests that the effect of leptin on the myocardial wall is at least partially independent of insulin action. Why a relation between plasma leptin levels and myocardial wall thickness occurs requires deeper investigation. Previous studies have reported that leptin may exert different effects on cardiovascular and neurohormonal systems. [21] [22] [23] [24] Briefly, leptin has been found to increase sympathetic nerve activity in the brown adipose tissue, kidney, hindlimb, and adrenal gland 22 in anesthetized Sprague-Dawley rats; this effect was dose dependent and slow in onset 22 but did not affect the cardiovascular system because of the presence of anesthesia. Later on, Shek et al 6 showed that chronic leptin infusion also increases arterial pressure and heart rate in conscious rats. The authors hypothesized that plasma leptin could affect heart rate and blood pressure through an increase in sympathetic activity or a withdrawal of parasympathetic tone. The relation between plasma leptin and the autonomic nervous system is strengthened by evidence of a direct relation between muscle sympathetic nerve activity and plasma leptin concentration. 21 Since sympathetic nervous system overactivity can play a role in increasing LVM in hypertensive patients, [7] [8] 25 one could hypothesize leptininduced sympathetic activation to have a role in the myocardial wall thickness of hypertensive patients. In the present study, plasma leptin concentration did not correlate with arterial blood pressure, most likely because of the very narrow range of the blood pressure levels in the hypertensive group.
On the other hand, leptin has been demonstrated to induce proliferation, differentiation, and functional activation of hemopoietic and embryonic cells. 26 -29 Thus, one could hypothesize that leptin might play a role in the functional activation of the cell at the myocardial level also. Nevertheless, only longitudinal studies designed to address the impact of plasma leptin levels on changes in cardiac function and structure will provide a strong evidence for a cause-effect relationship.
Interestingly, weight loss may reduce both plasma leptin 30 concentration and LVM. 31 Whether weight loss affects LVM through a reduction in plasma leptin concentration is a fascinating hypothesis. Unfortunately, the present study had a cross-sectional design; thus, only future studies will be able to respond to the possible pathophysiological link reported above.
An indirect finding of the present study was the lack of effect of acute hyperinsulinemia on plasma leptin concentration. Indeed, contrasting data regarding the possible influence of hyperinsulinemia on leptin levels have been reported. In fact, some [32] [33] [34] but not all 35 studies have shown plasma leptin levels to be unmodified by acute hyperinsulinemia. Differences in doses and length of insulin infusion, as well as in clinical characteristics of the population studied, might explain the discrepancy between the results found.
It is noteworthy that in the multivariate model, DBP was an independent determinant of SWT in the whole population but not in hypertensive patients alone. This could be explained by the wide range of DBP values in the whole population compared with the narrow range of the same parameter in the hypertensive group.
In conclusion, the present study demonstrates that FP leptin levels are associated with increased myocardial wall thickness independent of body composition and blood pressure levels in hypertensive insulin-resistant men. A leptin-induced sympathetic activation and/or cell proliferation could account for this effect of leptin on myocardial wall thickness. 
